筋萎縮性側索硬化症治療薬の世界市場成長(現状と展望)2024-2030年Global Amyotrophic Lateral Sclerosis Drugs Market Growth (Status and Outlook) 2024-2030 筋萎縮性側索硬化症(ALS)はルー・ゲーリッグ病またはシャルコー病とも呼ばれ、神経細胞が徐々に破壊され死滅する神経疾患である。 90%から95%の症例では原因が不明である。残りの5-10%は両親からの遺伝であ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー筋萎縮性側索硬化症(ALS)はルー・ゲーリッグ病またはシャルコー病とも呼ばれ、神経細胞が徐々に破壊され死滅する神経疾患である。90%から95%の症例では原因が不明である。残りの5-10%は両親からの遺伝である。これらの遺伝的ケースの約半数は、2つの特定の遺伝子のうちの1つが原因である。基本的な機序は、上下両方の運動ニューロンの損傷である。診断は、患者の徴候と症状に基づいて行われ、他の潜在的な原因を除外するために検査が行われる。 筋萎縮性側索硬化症治療薬の世界市場規模は、2023年の2億9350万米ドルから2030年には3億4610万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は2.4%と予測されています。 LPI(LPインフォメーション)の最新調査レポート「筋萎縮性側索硬化症治療薬産業予測」は、過去の売上高と2023年の筋萎縮性側索硬化症治療薬の世界総売上高に注目し、2024年から2030年までの筋萎縮性側索硬化症治療薬の予測売上高を地域別・市場分野別に包括的に分析しています。筋萎縮性側索硬化症治療薬の売上高を地域別、市場分野別、サブセクター別に分類し、世界の筋萎縮性側索硬化症治療薬産業の詳細な分析を百万米ドル単位で提供しています。 本インサイトレポートでは、世界の筋萎縮性側索硬化症治療薬の状況を包括的に分析し、製品区分、企業形成、売上高、市場シェア、最新動向、M&A活動に関する主要動向を明らかにしています。また本レポートでは、筋萎縮性側索硬化症治療薬のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当て、世界の主要企業の戦略を分析し、加速する世界の筋萎縮性側索硬化症治療薬市場におけるこれらの企業の独自の地位をより深く理解しています。 本インサイトレポートでは、筋萎縮性側索硬化症治療薬の世界的な見通しを形成している主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に分類して予測を行い、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの質的・量的市場インプットに基づいた透明性の高い手法により、本調査予測は筋萎縮性側索硬化症治療薬の世界における現状と将来の軌跡について非常にニュアンスの異なる見解を提供します。 世界の医薬品市場は2022年に1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要としている患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調しています。 本レポートでは、筋萎縮性側索硬化症治療薬市場の製品タイプ別、用途別、主要企業別、主要地域別および国別の包括的な概要、市場シェア、成長機会を紹介する。 タイプ別セグメント リルゾール エダラボン(ラジカヴァ) CoQ10 ブチルフタリド その他 用途別セグメント 病院薬局 小売薬局 オンライン薬局 本レポートは地域別にも市場を分割しています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 サノフィ 田辺三菱製薬 マイラン アポテックス グレマーク・ジェネリック サンファーマ コヴィス・ファーマ ルナン・ファーマ CSPCファーマシューティカル アセンド・ラボラトリーズ EISAI 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Amyotrophic Lateral Sclerosis Drugs Market Size 2019-2030 2.1.2 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Amyotrophic Lateral Sclerosis Drugs Segment by Type 2.2.1 Riluzole 2.2.2 Edaravone (Radicava) 2.2.3 CoQ10 2.2.4 Butylphthalide 2.2.5 Others 2.3 Amyotrophic Lateral Sclerosis Drugs Market Size by Type 2.3.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Type (2019-2024) 2.4 Amyotrophic Lateral Sclerosis Drugs Segment by Application 2.4.1 Hospital Pharmacies 2.4.2 Retail Pharmacies 2.4.3 Online Pharmacies 2.5 Amyotrophic Lateral Sclerosis Drugs Market Size by Application 2.5.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Application (2019-2024) 3 Amyotrophic Lateral Sclerosis Drugs Market Size by Player 3.1 Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Players 3.1.1 Global Amyotrophic Lateral Sclerosis Drugs Revenue by Players (2019-2024) 3.1.2 Global Amyotrophic Lateral Sclerosis Drugs Revenue Market Share by Players (2019-2024) 3.2 Global Amyotrophic Lateral Sclerosis Drugs Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Amyotrophic Lateral Sclerosis Drugs by Regions 4.1 Amyotrophic Lateral Sclerosis Drugs Market Size by Regions (2019-2024) 4.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 4.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 4.4 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 4.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 5 Americas 5.1 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Country (2019-2024) 5.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 5.3 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Region (2019-2024) 6.2 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 6.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Amyotrophic Lateral Sclerosis Drugs by Country (2019-2024) 7.2 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 7.3 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs by Region (2019-2024) 8.2 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 8.3 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030) 10.1.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030) 10.1.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast 10.1.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast 10.1.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast 10.1.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast 10.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030) 10.2.1 United States Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.2.4 Brazil Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030) 10.3.1 China Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.2 Japan Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.3 Korea Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.4 Southeast Asia Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.5 India Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.6 Australia Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030) 10.4.1 Germany Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.2 France Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.3 UK Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.4 Italy Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.5 Russia Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030) 10.5.1 Egypt Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.2 South Africa Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.3 Israel Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.4 Turkey Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.5 GCC Countries Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.6 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Type (2025-2030) 10.7 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 Sanofi 11.1.1 Sanofi Company Information 11.1.2 Sanofi Amyotrophic Lateral Sclerosis Drugs Product Offered 11.1.3 Sanofi Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 Sanofi Main Business Overview 11.1.5 Sanofi Latest Developments 11.2 Mitsubishi Tanabe Pharma 11.2.1 Mitsubishi Tanabe Pharma Company Information 11.2.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.2.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 Mitsubishi Tanabe Pharma Main Business Overview 11.2.5 Mitsubishi Tanabe Pharma Latest Developments 11.3 Mylan 11.3.1 Mylan Company Information 11.3.2 Mylan Amyotrophic Lateral Sclerosis Drugs Product Offered 11.3.3 Mylan Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Mylan Main Business Overview 11.3.5 Mylan Latest Developments 11.4 Apotex 11.4.1 Apotex Company Information 11.4.2 Apotex Amyotrophic Lateral Sclerosis Drugs Product Offered 11.4.3 Apotex Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Apotex Main Business Overview 11.4.5 Apotex Latest Developments 11.5 Glemark Generics 11.5.1 Glemark Generics Company Information 11.5.2 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Offered 11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Glemark Generics Main Business Overview 11.5.5 Glemark Generics Latest Developments 11.6 Sun Pharma 11.6.1 Sun Pharma Company Information 11.6.2 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.6.3 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 Sun Pharma Main Business Overview 11.6.5 Sun Pharma Latest Developments 11.7 Covis Pharma 11.7.1 Covis Pharma Company Information 11.7.2 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 Covis Pharma Main Business Overview 11.7.5 Covis Pharma Latest Developments 11.8 Lunan Pharma 11.8.1 Lunan Pharma Company Information 11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Lunan Pharma Main Business Overview 11.8.5 Lunan Pharma Latest Developments 11.9 CSPC Pharmaceutical 11.9.1 CSPC Pharmaceutical Company Information 11.9.2 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Offered 11.9.3 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 CSPC Pharmaceutical Main Business Overview 11.9.5 CSPC Pharmaceutical Latest Developments 11.10 Ascend Laboratories 11.10.1 Ascend Laboratories Company Information 11.10.2 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Offered 11.10.3 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.10.4 Ascend Laboratories Main Business Overview 11.10.5 Ascend Laboratories Latest Developments 11.11 EISAI 11.11.1 EISAI Company Information 11.11.2 EISAI Amyotrophic Lateral Sclerosis Drugs Product Offered 11.11.3 EISAI Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.11.4 EISAI Main Business Overview 11.11.5 EISAI Latest Developments 12 Research Findings and Conclusion
SummaryAmyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Amyotrophic Lateral Sclerosis Drugs Market Size 2019-2030 2.1.2 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Amyotrophic Lateral Sclerosis Drugs Segment by Type 2.2.1 Riluzole 2.2.2 Edaravone (Radicava) 2.2.3 CoQ10 2.2.4 Butylphthalide 2.2.5 Others 2.3 Amyotrophic Lateral Sclerosis Drugs Market Size by Type 2.3.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Type (2019-2024) 2.4 Amyotrophic Lateral Sclerosis Drugs Segment by Application 2.4.1 Hospital Pharmacies 2.4.2 Retail Pharmacies 2.4.3 Online Pharmacies 2.5 Amyotrophic Lateral Sclerosis Drugs Market Size by Application 2.5.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Application (2019-2024) 3 Amyotrophic Lateral Sclerosis Drugs Market Size by Player 3.1 Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Players 3.1.1 Global Amyotrophic Lateral Sclerosis Drugs Revenue by Players (2019-2024) 3.1.2 Global Amyotrophic Lateral Sclerosis Drugs Revenue Market Share by Players (2019-2024) 3.2 Global Amyotrophic Lateral Sclerosis Drugs Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Amyotrophic Lateral Sclerosis Drugs by Regions 4.1 Amyotrophic Lateral Sclerosis Drugs Market Size by Regions (2019-2024) 4.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 4.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 4.4 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 4.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024) 5 Americas 5.1 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Country (2019-2024) 5.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 5.3 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Region (2019-2024) 6.2 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 6.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Amyotrophic Lateral Sclerosis Drugs by Country (2019-2024) 7.2 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 7.3 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs by Region (2019-2024) 8.2 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024) 8.3 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030) 10.1.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030) 10.1.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast 10.1.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast 10.1.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast 10.1.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast 10.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030) 10.2.1 United States Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.2.4 Brazil Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030) 10.3.1 China Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.2 Japan Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.3 Korea Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.4 Southeast Asia Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.5 India Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.3.6 Australia Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030) 10.4.1 Germany Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.2 France Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.3 UK Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.4 Italy Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.4.5 Russia Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030) 10.5.1 Egypt Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.2 South Africa Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.3 Israel Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.4 Turkey Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.5.5 GCC Countries Amyotrophic Lateral Sclerosis Drugs Market Forecast 10.6 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Type (2025-2030) 10.7 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 Sanofi 11.1.1 Sanofi Company Information 11.1.2 Sanofi Amyotrophic Lateral Sclerosis Drugs Product Offered 11.1.3 Sanofi Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 Sanofi Main Business Overview 11.1.5 Sanofi Latest Developments 11.2 Mitsubishi Tanabe Pharma 11.2.1 Mitsubishi Tanabe Pharma Company Information 11.2.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.2.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 Mitsubishi Tanabe Pharma Main Business Overview 11.2.5 Mitsubishi Tanabe Pharma Latest Developments 11.3 Mylan 11.3.1 Mylan Company Information 11.3.2 Mylan Amyotrophic Lateral Sclerosis Drugs Product Offered 11.3.3 Mylan Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Mylan Main Business Overview 11.3.5 Mylan Latest Developments 11.4 Apotex 11.4.1 Apotex Company Information 11.4.2 Apotex Amyotrophic Lateral Sclerosis Drugs Product Offered 11.4.3 Apotex Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Apotex Main Business Overview 11.4.5 Apotex Latest Developments 11.5 Glemark Generics 11.5.1 Glemark Generics Company Information 11.5.2 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Offered 11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Glemark Generics Main Business Overview 11.5.5 Glemark Generics Latest Developments 11.6 Sun Pharma 11.6.1 Sun Pharma Company Information 11.6.2 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.6.3 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 Sun Pharma Main Business Overview 11.6.5 Sun Pharma Latest Developments 11.7 Covis Pharma 11.7.1 Covis Pharma Company Information 11.7.2 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 Covis Pharma Main Business Overview 11.7.5 Covis Pharma Latest Developments 11.8 Lunan Pharma 11.8.1 Lunan Pharma Company Information 11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered 11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Lunan Pharma Main Business Overview 11.8.5 Lunan Pharma Latest Developments 11.9 CSPC Pharmaceutical 11.9.1 CSPC Pharmaceutical Company Information 11.9.2 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Offered 11.9.3 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 CSPC Pharmaceutical Main Business Overview 11.9.5 CSPC Pharmaceutical Latest Developments 11.10 Ascend Laboratories 11.10.1 Ascend Laboratories Company Information 11.10.2 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Offered 11.10.3 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.10.4 Ascend Laboratories Main Business Overview 11.10.5 Ascend Laboratories Latest Developments 11.11 EISAI 11.11.1 EISAI Company Information 11.11.2 EISAI Amyotrophic Lateral Sclerosis Drugs Product Offered 11.11.3 EISAI Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.11.4 EISAI Main Business Overview 11.11.5 EISAI Latest Developments 12 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
LP Information 社の最新刊レポート本レポートと同じKEY WORD(lateral)の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/05 10:26 153.43 円 167.28 円 201.52 円 |